Mereo BioPharma (MREO) Invested Capital (2017 - 2023)

Mereo BioPharma (MREO) has reported Invested Capital for 7 consecutive years, with $9.8 million the latest figure, recorded in Q2 2023.

• In Q2 2023, Invested Capital fell 51.09% year-over-year to $9.8 million; the TTM figure through Mar 2024 stood at $9.8 million (down 81.28% YoY), while the FY2022 annual figure was $13.0 million, down 32.94% from the prior year.
• Invested Capital retreated to $9.8 million in Q2 2023 per MREO's latest filing, from $13.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $34.5 million in Q2 2020 and bottomed at $9.8 million in Q2 2023.
• Historically, Invested Capital has averaged $21.2 million across 5 years, with a median of $20.7 million in 2020.
• Annual changes were most pronounced in 2020 — Invested Capital jumped 35.81% — and 2023, when it slumped 51.09%.
• Mereo BioPharma's Invested Capital stood at $26.4 million in 2019, then slipped by 19.18% to $21.3 million in 2020, then dropped by 9.03% to $19.4 million in 2021, then tumbled by 32.94% to $13.0 million in 2022, then decreased by 24.44% to $9.8 million in 2023.
• Business Quant data shows MREO's Invested Capital at $9.8 million in Q2 2023, $13.0 million in Q4 2022, and $20.1 million in Q2 2022.